<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ROSUVASTATIN</span><br/>(ro-su-va-sta'ten)<br/><span class="topboxtradename">Crestor<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antilipemic</span>; <span class="classification">hmg-coa reductase inhibitor (statin)</span><br/><b>Prototype: </b>Lovastatin<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 20 mg, 40 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Rosuvastatin is a potent inhibitor of HMG-CoA reductase, an enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid,
         an early and rate-limiting step in cholesterol biosynthesis. Interference with this enzyme's activity reduces the quantity
         of mevalonic acid, a precursor of cholesterol.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces total cholesterol and LDL cholesterol, and also lowers plasma triglycerides and apolipoprotein B while increasing
         HDL.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to diet for the reduction of LDL cholesterol and triglycerides in patients with primary hypercholesterolemia and mixed
         dyslipidemia.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any component of the product, active liver disease, pregnancy (category X), women of child-bearing potential
         not using appropriate contraceptive measures, lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concomitant use of cyclosporine and gemfibrozil, excessive alcohol use or history of liver disease, renal impairment, advanced
         age, hypothyroidism.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hyperlipidemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg once daily (540 mg/d), max dose 40 mg/d. If taking cyclosporine, start with 5 mg/d.<br/><span class="rdage">Geriatric:</span> <span class="rdroute"></span> Initial dose of 5 mg/d. <br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Persons of Asian descent may be slow metabolizers and may require half the normal dose.</li>
<li>May give any time of day without regard to food.</li>
<li>Store at or below 30° C (86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, back pain, flu syndrome, chest pain, infection, pain, peripheral edema. <span class="typehead">CNS:</span> Headache, dizziness, insomnia, hypertonia, paresthesia, depression, anxiety, vertigo, neuralgia. <span class="typehead">CV:</span> Hypertension, angina, vasodilatation, palpitations. <span class="typehead">GI:</span> Diarrhea, dyspepsia, nausea, abdominal pain, constipation, gastroenteritis, vomiting, flatulence, gastritis. <span class="typehead">Endocrine:</span> Diabetes. <span class="typehead">Hematologic:</span> Anemia, ecchymosis. <span class="typehead">Musculoskeletal:</span> Myalgia, arthritis, arthralgia, rhabdomyolysis (especially with dose &gt;40 mg). <span class="typehead">Respiratory:</span> Pharyngitis, rhinitis, sinusitis, bronchitis, increased cough, dyspnea, pneumonia, asthma. <span class="typehead">Skin:</span> Rash, pruritus. <span class="typehead">Urogenital:</span> UTI. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Cyclosporine,</b>
<b>gemfibrozil,</b>
<b>niacin,</b> may increase risk of rhabdomyolysis; <small>ANTACIDS</small> may decrease rosuvastatin absorption; may cause increase in INR with <b>warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed. <span class="typehead">Peak:</span> 35 h. <span class="typehead">Metabolism:</span> Limited metabolism in the liver (not CYP 3A4). <span class="typehead">Elimination:</span> Eliminated primarily in feces (90%). <span class="typehead">Half-Life:</span> 20 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report promptly S&amp;S of myopathy (e.g., skeletal muscle pain).</li>
<li>Withhold drug and notify physician if CPK levels are markedly elevated (<img src="../images/special/greaterorequal.gif"/>10<small>x</small>ULN)
            or if myopathy is diagnosed or suspected.
         </li>
<li>Lab tests: CPK levels for S&amp;S of myopathy; periodic LFTs; more frequent INR values with concomitant warfarin therapy.</li>
<li>Monitor CV status, especially with a known history of hypertension or heart disease.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not take antacids within 2 h of taking this drug.</li>
<li>Do not breast feed while taking this drug.</li>
<li>Females should use reliable means of contraception while taking this drug to prevent pregnancy.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>